Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

3153 psych > parkinson's > Flashcards

parkinson's Flashcards

(67 cards)

Start Studying
1
Q

3 features of PD — pathophysiology

A
  • Lewy bodies
  • degeneration of dopaminergic neurons
  • basal ganglia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

lewy bodies

A
  • Accumulation of aggresomes (aggregated proteins)
    • Lewy bodies ~ deposits of a-synuclein and ubiquitin
    • Eosinophilic cytoplasmic inclusions
  • apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

degeneration of dopaminergic neurons, substantia nigra

A
  • Lewy body inclusion in substantia nigra
    • Induce oxidative stress, nitric stress
    • Molecular abnormalities
  • Dysfunction of nigrostriatal pathway
    • Loss of darked region
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

basal ganglia and motor control

A
  • Affects motor control
  • Involved in action selection
  • Normally inhibit a number of motor systems
    • Substantia nigra-mediated release of inhibition permits a motor system to become active
    • Involves both excitatory D1 and inhibitory D2 receptors
  • Loss of substantia nigra –> no release of inhibition –> hypokinetic state
  • Strong connection to other areas
    • Thalamus, motor cortex etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

indirect vs direct pathways (basal ganglia)

A

DIRECT: hypoactivation of excitatory D1 receptors
* Weaken striatal inhibition of Globus pallidus internal
* Va/VL thalamus excites more motor pathway

INDIRECT: hypoactivation of inhibitory D2 receptors
* Strengthen striatal inhibition of GPe (external)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

neurotransmitter deficiency – PD

A
  • Striatal dopaminergic deficiency
    * Extrapyramidal motor sx (tremor, rigidity, bradykinesia)
  • Other neurotransmitters involved
    * Non-motor sx
    * Autonomic, psychiatric, sensory, ocular, gait imbalance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

cardinal features of PD

A
  • Tremor at rest
  • Bradykinesia (slowness of movement)
    * micrographia (smaller handwriting)
  • Rigidity (cogwheeling)

postural instability and gait disturbances
* stooped posture, reduced arm swing, masked facial expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

progressives features of PD

A
  • Early yrs of disease: Rate of disability progression marked
  • 10-15yrs after onset: Sig disability
  • Later stage: pt more dependent in their activities of daily living
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

initial presentation

A
  • Asymmetric
  • +ve response to levodopa/ apomorphine (DA agonists)
  • NOT PRESENT: Postural instability (& falls)
  • NOT PRESENT: Autonomic dysfunction
  • Less rapid progression
  • Impaired olfaction ?

Can conduct neuroimaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

progressed disease

A
  • Unable to perform basic ADLs (or cannot perform safely)
    ○ Mobility (walk, use stairs)
    ○ Feeding self
    ○ Grooming, personal hygiene
    ○ Toileting
    ○ Showering/ bathing
    ○ Continence (bowel, bladder)
  • Choking
  • Pneumonia (from aspiration into lungs)
  • Falls (mobility deficit)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

progressive sx of PD

A
  • Motor sx: fluctuations, dyskinesias
  • Non-motor sx (fall, postural instability, postural hypotension, confusion, dementia - PDD, suboptimal nutrition, speech, sleep d/o)
  • PDD: Parkinson’s Disease Dementia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PD timeline

A
  • 20 yr prodrome
    * hyposmia, constipation, bladder disorder
    * sleep d/o, obesity, dep
  • clinical onset
    * unilateral: tremor, rigidity, akinesia
  • II: bilateral disease
  • III: poor balance
  • IV: falls, dependency, cognitive decline
  • V: chair/ bed bound, dementia (PDD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

measurement of disease progression

A
  • Hoehn and Yahr staging
    * prodrome –> I,II,III,IV,V (across 20 yrs)
  • MDS: Unified Parkinson’s Disease Rating Scale (UPDRS)
    * research tool
    * intellect, Activities of daily living, motor exam, complication of therapy (dyskinesia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

dx of PD

A
  • Based on clinical sigs, physical examination, hx taking = 2/3 cardinal signs present
    • Tremor
      ○ Resting, disappears with movement,, incr with stress
    • Rigidity
      ○ Cogwheel rigidity, leadpipe rigidity
    • Bradykinesia
      ○ Weakness, loss of dexterity, loss of facial exp, difficulty getting out of bed/chair, turning (walking), reduced blinking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

overall parkinson tx strategies

A
  • incr central DOPA/ dopaminergic transmission (levodopa+DCI, DA)
    * L-tyrosine —> L-dopa (pass through BBB)
    * L-dopa —-> dopamine (DOPA decarboxylase)
  • decr breakdown (COMTi, MAO-Bi)
    * dopamine reuptake by presynaptic neuron
    * enzymes: COMT, MAO-B
  • correct imbalances in other neurotransmitter pathways
    * anticholinergics, NMDA antagonist (glutamate)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

tx plan based on onset

A
  • Early/ young onset PD = [Dopamine agonist] > levodopa (dyskinesia)
    • Slower disease progression
    • Features
      ○ < cognitive decline
      ○ Earlier motor complications
      ○ Dystonia (common initial presentation)
  • Late -onset [poor levodopa response]
    • Falls and freezing
    • rapid course
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

goals of PD management

A
  • Manage sx
  • Maintain function & autonomy

No tx because PD is progressive, no neuroprotection available

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

levodopa MOA

A

Incr precursor to incr dopamine synthesis
L-dopa –> dopamine (DOPA decarboxylase, MAO, COMT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

concomitant with

A
  • decarboxylase inhibitors: carbidopa/ benserazide
    • Peripheral DCI (Prevent peripheral dopamine SE)
    • Incr dopamine avail in central (convert to dopamine)
    • incr F from 33% –> 75%
    • not cross BBB

75-100mg OD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ratio of sinemet (carbidopa) , Madopar (benserazide)

A

DCI: LEVO

1 : 4 (Sinemet, Madopar)
1 : 10 (Sinemet)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

indication for levodopa

A
  • Gold standard – bradykinesia, rigidity
    * less for speech, postural reflex, gait disturbances
  • Efficacious for sx management of early & late PD * but Low dose and Preferable to start at later stage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

ADR of levodopa

A
  • ST: NV, postural hypoTENsion, drowsy, hallucination, psychosis
  • LT: motor fluctuations, dyskinesia (3-5yrs of initiate)
    Irreversible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

dyskinesia presentation + management

A

○ Involuntary, uncontrolled
○ Twitching, jerking
○ Peak dose dyskinesia (right after admin - due to lowered dyskineisa threshold)
* Reduce dose// use sustained release
○ Dystonia

  • Management:
    * amantadine
    * replace specific dose w/ modified release levodopa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

dyskinesia stage of levodopa

A
  • stable phase
    * motor function near normal (reach sx relief threshold)
    * conc fluctuate w/o sx emergence
  • wearing off –> dyskinesia
    * duration of motor response shortens
    * sx appears b. doses (in morning)
  • peak dose dyskinesia
  • on-off phenomenom
    * severe fluctuations
    * Appear at random but related to swings in drug conc
    * Often and normal mobility difficult to achieve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
manage wearing-off dyskinesia sx
* Sustained release forms - Release levo/DCI over long period 4-6hrs - Lower F (dose adj needed) ○ IR --> CR: incr dose 25-50% ○ CR --> IR: dose decr - Reduce morning stiffness (take last dose of day, pt can get through OM) ○ No crush, open capsule
26
DDI of levodopa
* Pyridoxine * Cofactor for dopa decarboxylase ○ Take levo + DCI * HIGH DOSE: Vit B6 (haem issues)/ vit B complex tabs * Fe * Decr absorption of levo (space out admin) * Protein (food, protein powder) * Decr absorption of levo (space out admin) * Dopamine antagonists * Metoclopramide, prochlorperazine ○ Switch to domperidone (antiemetic) * FGA * SGA: risperidone * MAOi (within 14d) - incr NE = hypotensive
27
COMPTi MOA catechol-O-methyltransferase
* Block COMT conversion of dopamine/ L-DOPA into inactive form (major metaboliser) * More levodopa available to enter brain ○ Reduce required dose, less SE ○ Incr duration of each Levodopa dose ○ Beneficial in tx wearing off response Entacapone, Tolcapone
28
indication of COMPTi
* Adjunct w/ levodopa (decr off-time, enhancer) * decr wearing off effects * (not monotherapy) * Entacapone (selective, reversible), Tolcapone
29
eg of COMTi drugs
* Comtan: entacapone * Stalevo: levo + carbidopa + entacapone * Reduce pill burden, but hard to titrate
30
COMPTi ADR
* Liver dysfunction (Tolcapone affects CYP450) * D * Urinary discolouration (ORANGE) * Visual hallucinations potentiate dopaminergic effects * Incr abnormal movements, dykinesia - initiation * Much milder than Levodopa SE * decr levodopa dose (reduce dyskineisa in LT) * hypotension, NV Dopamine needed to regulate these cycles - Sensory function - Sleep/wake funct
31
DDI of COMTi
- Fe, Ca - MAOi (ok with MAO-Bi) ○ Caution with MAO-Ai - Catecholamine drug - Warfarin ○ Enhances anticoag effect
32
MAO-Bi MOA
selegiline, rasagiline Irreversible inhibit enzyme MAO B from breakdown of dopamine (MAY) delay nigral brain cell degeneration Neuroprotective effects
33
indication of MAO-Bi
* MONOTHERAPY Early stage of PD (Selegiline) * symptomatic monotherapy * adjunct in later stages
34
dose of MAO-Bi
* Selegiline (deprenyl, eldepryl, jumex) * 5mg OD-BD (2nd dose in afternoon X ON) ○ Liver metabolise to amphetamines (stimulating, no MAO-B effect) * DATATOP: has vit E * Rasagilin (Azilect) * Not metabolised to amphetamines * 0.5-2mg OD
35
pk of MAO-Bi
- Short t1/2 (1.5 - 4hrs) * Long duration of action (irreversible + MAO only regenerate in 14-28d) - Metabolised for selegiline * Liver --> amphetamines (stimulating)
36
ADR of MAO-Bi
* heartburn, LOA * ANX, palpitation, insomnia * nightmare, visual hallucination
37
MAO-A vs B
MAO-A: peripheral, NA, 5HT (antidep- reversible RIMA) MAO-B: central, DA * MAO regenerates on 14-28d * Irreversible MAO-B inhibitors (not totally selective, has MAO-A effect too)
38
MAO-Bi DDI
- SSRI, SNRI, TCA (need washout) - Pethidine, tramadol (opioids) - Linezolid, dextromethorphan - DA - Sympatomimetics: nasal decongestants (pseudoephedrine) - Other MAOi
39
MAO-Bi FDI
- Tyramine (metabolised by MAO-A, MAO-B): displace NA ○ More NA = hypotension - Fermented food, aged cheese, beer
40
dopamine receptor agonist MOA
pramipexole, pergolide, ropinirole * act directly on dopamine receptors in brain, reduce PD sx (antiparkinsonian effects) * mimic DA action, bind to D2 receptor in basal ganglia * prevent/ delay onset of motor complications
41
indication of DA RA
* MONO in Younger PD pt * Fewer SE, if sx not as bad use this instead of levo * delay levodopa (also has less motor complications) * Adjunct to levo for mod-severe pts * Manage motor complications by levo * Neuroprotective? Disease modifying??
42
ergot derivative (DA agonist)
bromocriptine (NMS, hyperprolact) cabergoline (0.5mg dostinex) pergoline (not in sg)
43
non-ergot derivative DA agonist
ropinirole pramipexole (IR, SR form) rotigotine (patch, exemption item) apomorphine (sc inj not in SG)
44
PK of DA agonist
- F: * ERGOT derived < NON-ERGOT derived * Extensive 1st pass metabolism - T1/2, DOA (>levo) - Metabolism (Non-ergot) * ropinirole: liver --> inactive metabolites * Pramipexole: excrete unchanged in urine
45
DA agonist cautions DO NOT USE
Liver impairment (non-ergot ropinirole) Urine impairment (non-ergot Pramipexole )
46
DA agonist ADR
* peripheral DA: NV, orthostatic hypoTENsion, oedema less motor complications than LEVO * central DA: Headache, dizzy, hallucination (visual), somnolence, compulsive behaviours more than LEVO * non-DA (more risk with ERGOT): fibrosis, valvular HD, cardia arrhythmia
47
eg DA agonist ADR
* Pergolide (ergot derivative) * Peritoneal fibrosis * Cardiac valve regurgitation * Pramipexole, ropinirole (non-ergot): * Sedation, somnolence, daytime sleepy
48
NMDA antagonist MOA N-methyl D-aspartate
amantadine 1) enhance release of stored DA 2) inhibit presynaptic uptake of DA 3) anti- glutamatergic activity --> decr activate NMDA receptor --> less cell apoptosis, reduce excitotoxicity
49
NMDA antagonist indications
* Manage Levodopa-induced dyskinesias * Adjunctive * 2nd dose in afternoon, stimulating (not ON) * NMS, EPSE (tardive dyskinesia - FGA), hyperprolact
50
caution for NMDA
renal impair (dose reduction) * CL: renal
51
ADR of NMDA antagonist
* N, Cognitive impairment (inability to conc) * light head, confuse * Hallucinate, insomnia, nightmare * Livedo reticularis (venule swell from thrombosis --> risk PE) * Reticulated discoloration of limbs
52
memantine vs amantadine
* non-competitive inhibitor NMDA * No good evidence for effect on levodopa-induced dyskinesias amantadine * NMDA antagonist, anticholinergic * upregulate + sensitivity D2 receptors
53
anticholinergics eg
* Trihexyphenidyl (benzhexol) * Biperiden * Orphenadrine * procyclidine * benztropine
54
anticholinergics MOA
Peripheral acting agents useful in tx sialorrhea (excess saliva flow, tremor): Ach PNS effect - rest, digest inhibit PNS: selective block ACh receptors in nerve cells
55
indication for anticholinergics
* Sx monotherapy * Adjunct to levodopa * Tremor, stiffness in PD * NOT FOR: bradykinesia, dyskinesia sx
56
ADR of anticholinergics
* Block parasympathetic system (rest, digest): * Dry mouth, sedation, constipation, urinary retention, delirium, confusion, hallucinations
57
tx individualised by
age stage of disease (early vs late) lvl of activity (type of daily activity) assoc psychological factors assoc medical conditions drug-induced? pt factors
58
pharm tx for non-motox sx
* dementia (AChEi) * DEP (DA, SSRI, SNRI) * psychosis (APS, AChEi) * sleep d/o (BZP, melatonin) * autonomic dysfunction * constipation (osmotic PEG) * GI motility (domperidone, peripheral DA antagonist) * ortho hyoTEN (domperidone, vasopressor, AChEi) * sialorrhoea (anticholinergic, neurotoxin) * fatigue (stimulant)
59
CAM
* co-enzyme Q10 + vit E (early): safe, ineffective * creatine (safe, ineffective) * vit E 1200 IU (neuroprotective??) * glutathione * riboflavin * lipoic acid * acetyl carnitine * curcumin
60
non pharm
- PT ○ Stretching, transfers, posture, walking (add guiding lines) - OT ○ Mobility aids, home & workplace safety - Speech and swallowing ○ Degree pt can swallow (viscosity level) - Surgery
61
drug-induced parkinsonism presentation - Difficult to distinguish from PD - May be underlying iPD (20%)
Bilateral sx Elderly Acute, subacute onset Poor response to levodopa Uncommon for rest tremor
62
DIP tx
* onset of DIP ~3mnths * Tx: withdraw offending drug * Withdrawal of drug leads to improvement * 80% of pt, within 8wks * anticholinergics, amantadine ST use
63
high potential risk of DIP (decr DA, neurotransmitters)
* DA (D2) receptor blockers * APS (FGA > SGA high dose) * DA depleters (tetrabenazine, reserpine) * DA synthesis blockers (a-methyldopa) * Ca channel antagonist (flunarizine, cinnarizine)
64
intermediate potential risk of DIP
* SGA * Ca channel antagonists * dilitiazem, verapamil * anti-seizure * VA, PHT, levetiracetam * antiemetic * metoclopramide, prochlorperazine * mood stabiliers (Li)
65
motor sx, activities of daily living
levodopa (some improvement): DA, MAO-Bi
66
motor complications ADR
levo > DA, MAOBi
67
ADE
DA > levodopa, MAOBi (specified ADE: peripheral, central, non-DA) (levodopa less ADE, but afer 3-5yrs, more complicatd ADE)

3153 psych (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions